Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F14%3A10283005" target="_blank" >RIV/00216208:11150/14:10283005 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1038/leu.2014.2" target="_blank" >http://dx.doi.org/10.1038/leu.2014.2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/leu.2014.2" target="_blank" >10.1038/leu.2014.2</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma
Popis výsledku v původním jazyce
The inhibitor of apoptosis (IAP) proteins have a critical role in the control of apoptotic machinery, and has been explored as a therapeutic target. Here, we have examined the functional importance of IAPs in multiple myeloma (MM) by using a Smac (secondmitochondria-derived activator of caspases)-mimetic LCL161. We observed that LCL161 was able to potently induce apoptosis in some MM cell lines but not in others. Examining the levels of X-linked inhibitor of apoptosis protein (XIAP), cellular inhibitorof apoptosis protein 1 (cIAP1) and cellular inhibitor of apoptosis protein 2 (cIAP2) post LCL161 treatment indicated clear downregulation of both XIAP activity and clAP1 levels in both the sensitive and less sensitive (resistant) cell lines. clAP2, however, was not downregulated in the cell line resistant to the drug. Small interfering RNA-mediated silencing of clAP2 significantly enhanced the effect of LCL161, indicating the importance of downregulation of all IAPs simultaneously for i
Název v anglickém jazyce
Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma
Popis výsledku anglicky
The inhibitor of apoptosis (IAP) proteins have a critical role in the control of apoptotic machinery, and has been explored as a therapeutic target. Here, we have examined the functional importance of IAPs in multiple myeloma (MM) by using a Smac (secondmitochondria-derived activator of caspases)-mimetic LCL161. We observed that LCL161 was able to potently induce apoptosis in some MM cell lines but not in others. Examining the levels of X-linked inhibitor of apoptosis protein (XIAP), cellular inhibitorof apoptosis protein 1 (cIAP1) and cellular inhibitor of apoptosis protein 2 (cIAP2) post LCL161 treatment indicated clear downregulation of both XIAP activity and clAP1 levels in both the sensitive and less sensitive (resistant) cell lines. clAP2, however, was not downregulated in the cell line resistant to the drug. Small interfering RNA-mediated silencing of clAP2 significantly enhanced the effect of LCL161, indicating the importance of downregulation of all IAPs simultaneously for i
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Leukemia
ISSN
0887-6924
e-ISSN
—
Svazek periodika
28
Číslo periodika v rámci svazku
7
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
10
Strana od-do
1519-1528
Kód UT WoS článku
000339705500018
EID výsledku v databázi Scopus
—